Nykode Therapeutics Stock
Stocks
VACC
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Oslo Bors
17:41:37 08/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.430 NOK | -2.70% |
|
-3.92% | +42.21% |
| 09-28 | Nykode Therapeutics Gets Unfavorable Tax Appeal Board Ruling, Plans to Seek Review | MT |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| Market Cap | 1.15B 120M 107M 100M 90.99M 171M 11.62B 173M 1.2B 470M 5.91B 451M 441M 19.01B | P/E 2026 * |
-5.37x | P/E 2027 * | 67.1x |
|---|---|---|---|---|---|
| Enterprise Value | 662M 69.16M 61.8M 57.65M 52.37M 98.63M 6.69B 99.37M 693M 271M 3.4B 260M 254M 10.94B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 2.42x |
| Free-Float |
76.21% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Oslo Bors
| VACC | Real-time | |
CBOE
| Real-time | ||
|
Nasdaq Stockholm
| NYKD O | Delayed | |
|
OTC Markets
| VACBF | Delayed | |
|
Börse Stuttgart
| 5VB | Delayed | |
|
Boerse Muenchen
| 5VB | Real-time | |
|
Deutsche Boerse AG
| 5VB | Delayed | |
|
CBOE
| Real-time |
Last Transcript: Nykode Therapeutics
| 1 day | -2.70% | ||
| 1 week | -3.92% | ||
| Current month | -3.92% | ||
| 1 month | -14.78% | ||
| 3 months | +12.83% | ||
| 6 months | +5.70% | ||
| Current year | +42.21% |
| 1 week | 3.4 |  | 3.69 |
| 1 month | 3.4 | | 4.22 |
| Current year | 2.21 | | 5.2 |
| 1 year | 1.7 | | 5.2 |
| 3 years | 1.44 | | 23.1 |
| 5 years | 1.44 | | 85.3 |
| 10 years | 1.44 | | 93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Engsig
CEO | Chief Executive Officer | 54 | 01/01/2019 |
| President | 49 | 01/01/2017 | |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 03/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 23/04/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/03/25 | Buy | Company | 3,000,000 | 0.9187% | ||
| 20/12/24 | Buy | Director | 100,000 | 0.0306% | ||
| 20/12/24 | Sell | Director | 100,000 | 0.0306% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.70% | -3.92% | +96.00% | -84.48% | 120M | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.68B | |
| -13.31% | -13.59% | +5.82% | +55.72% | 58.7B | |
| -1.87% | +1.50% | +4.44% | +32.63% | 48.36B | |
| -3.76% | -2.14% | +331.33% | +702.20% | 43.05B | |
| -0.90% | -3.99% | +28.50% | +29.94% | 42.48B | |
| -4.35% | -0.52% | +6.56% | +109.35% | 41.39B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.29B | |
| -1.89% | -3.10% | -10.19% | -14.35% | 23.93B | |
| -3.66% | -10.86% | -37.32% | +316.28% | 22.22B | |
| Average | -2.76% | -2.09% | +48.37% | +129.41% | 38.62B | |
| Weighted average by Cap. | -2.69% | -1.56% | +49.76% | +145.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 214M 22.31M 19.93M 18.6M 16.89M 31.81M 2.16B 32.05M 223M 87.31M 1.1B 83.75M 81.94M 3.53B |
| Net income | -211M -22.07M -19.72M -18.4M -16.71M -31.47M -2.13B -31.7M -221M -86.36M -1.09B -82.85M -81.05M -3.49B | 11.3M 1.18M 1.05M 983K 893K 1.68M 114M 1.69M 11.82M 4.62M 58.03M 4.43M 4.33M 187M |
| Net Debt | -489M -51.01M -45.58M -42.52M -38.62M -72.74M -4.93B -73.28M -511M -200M -2.51B -191M -187M -8.07B | -634M -66.2M -59.15M -55.19M -50.13M -94.41M -6.4B -95.11M -663M -259M -3.26B -249M -243M -10.47B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/10/26 | NOK 3.430 | -2.70% | 735,409 |
| 07/10/26 | NOK 3.525 | -0.84% | 499,985 |
| 06/10/26 | NOK 3.555 | -1.11% | 417,038 |
| 05/10/26 | NOK 3.595 | +3.45% | 494,432 |
| 02/10/26 | NOK 3.475 | +0.72% | 407,047 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
Select your edition
All financial news and data tailored to specific country editions
